Skip to main content

Table 3 Most common TEAEs by grade

From: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

TEAE occurring in >10% of patients, n (%)a NCI CTCAE grade (n = 104)
Total 1 2 3 4 5
Any AE 104 (100.0) 8 (7.7) 37 (35.6) 37 (35.6) 13 (12.5) 8 (7.7)
Muscle spasms 74 (71.2) 45 (43.3) 23 (22.1) 6 (5.8) 0 0
Alopecia 69 (66.3) 49 (47.1) 20 (19.2) NA NA NA
Dysgeusia 58 (55.8) 32 (30.8) 26 (25.0) NA NA NA
Weight decreased 54 (51.9) 29 (27.9) 16 (15.4) 9 (8.7) NA NA
Fatigue 45 (43.3) 33 (31.7) 7 (6.7) 4 (3.8) 1 (1.0) 0
Nausea 34 (32.7) 25 (24.0) 9 (8.7) 0 0 0
Decreased appetite 29 (27.9) 19 (18.3) 7 (6.7) 3 (2.9) 0 0
Diarrhea 28 (26.9) 20 (19.2) 5 (4.8) 3 (2.9) 0 0
Constipation 20 (19.2) 14 (13.5) 6 (5.8) 0 0 0
Cough 20 (19.2) 16 (15.4) 4 (3.8) 0 NA NA
Vomiting 18 (17.3) 15 (14.4) 3 (2.9) 0 0 0
Arthralgia 17 (16.3) 12 (11.5) 4 (3.8) 1 (1.0) 0 0
Headache 15 (14.4) 12 (11.5) 3 (2.9) 0 NA NA
Nasopharyngitis 13 (12.5) 11 (10.6) 2 (1.9) 0 0 0
SCC 12 (11.5) 3 (2.9) 5 (4.8) 3 (2.9) 0 0
Ageusia 12 (11.5) 8 (7.7) 4 (3.8) NA NA NA
Hypogeusia 11 (10.6) 10 (9.6) 1 (1.0) NA NA NA
Pruritus 11 (10.6) 8 (7.7) 2 (1.9) 1 (1.0) NA NA
Dyspepsia 11 (10.6) 8 (7.7) 3 (2.9) 0 NA NA
  1. AE adverse event, NA not applicable, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, SCC squamous cell carcinoma, TEAE treatment-emergent adverse event
  2. aMedical Dictionary for Regulatory Activities–preferred term